061 What factors predict good patient experiences of switching from reference etanercept to an etanercept biosimilar in a South West London general hospital? [PDF]
, 2018 Laura Attipoe +5 more
openalex +1 more source
Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARD), targeted synthetic DMARD (tsDMARD) and biosimilar DMARD (bsDMARD) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity [PDF]
, 2023 Juthamas Prawjaeng +7 more
openalex +1 more source
The Sicilian network of biological therapy in inflammatory bowel disease: preliminary data on efficacy . [PDF]
, 2017 Background and aim: The monitoring of appropriateness and costs of biological therapy in Inflammatory bowel disease (IBD) is a relevant need. We aimed to evaluate appropriateness, efficacy and safety of biological therapy in IBD in Sicily through a web ...
Accomando S. +26 more
core +1 more source
Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis [PDF]
, 2016 Radan Keil +18 more
openalex +1 more source
The relationship between biologicals and innovation [PDF]
, 2015 There are no two European countries with the same – or even similar – health care systems. But they share one common denominator: in all European countries the costs for health care keep on rising faster than their GDP.
Crommelin, Daan J.
core
The Knowledge, Opinions, Attitudes of Physicians About Biosimilar Drugs: A University Hospital Data
, 2022 Ebru GÖKDEMİR +4 more
openalex +2 more sources
Biosimilar insulin: the current landscape [PDF]
, 2017 Andrea Llano, Miles Fisher, Gerry McKay
openalex +1 more source